Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance
- PMID: 28296013
- DOI: 10.1111/liv.13416
Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance
Abstract
Background & aims: The difference between the long-term outcome of low-viraemic (HBV-DNA≤20 000-IU/mL, LV-AC) and inactive HBsAg carriers (HBV-DNA≤2000-IU/mL, IC) remains to be defined. We studied prospectively 153 HBeAg-negative HBsAg-carriers with baseline HBV-DNA≤20 000-IU/mL and normal transaminases.
Methods: IC, LV-AC or chronic hepatitis B (CHB) (HBV-DNA persistently ≤2000-IU/mL, ≤20 000-IU/mL or >20 000-IU/mL respectively) were diagnosed after 1-year, 3-monthly monitoring. Thereafter IC and LV-AC were followed-up for additional 57.2 (8.5-158.3) months. HBV-DNA, HBsAg, HBV"core-related"Antigen (HBcrAg) and total-anti-HBc were quantified at baseline.
Results: After the 1st year diagnostic follow-up CHB [higher HBV-DNA (P=.005), total-anti-HBc (P=.012), ALT (P=.007) and liver-stiffness (P=.021)] was identified in 20 (13.1%) carriers; baseline HBsAg≤1000IU/HBV-DNA≤2000IU/mL excluded the presence of CHB (NPV-100%). Thereafter, during the long-term follow-up none of 87 IC reactivated, 19 (21.8%) cleared HBsAg [older-age (P=.004), lower HBsAg (P<.001), higher yearly HBsAg decline (P<.001)]. Twenty-five of 46 (54.3%) LV-AC remained stable, 20 (43.5%) became IC and 1 (2.2%) developed CHB. The best single-point CHB and IC diagnostic-accuracies were total-anti-HBc (84.2%, NPV-98.2%) and HBV-DNA/total-anti-HBc/HBcrAg combination (89.5%, 93%-sensitivity, 84.8%-specificity) respectively.
Conclusions: Viraemia persistently ≤20 000-IU/mL predicts a benign clinical outcome: it was associated with transition to IC in 43% of LV-AC and to Occult HBV Infection in 20% of IC within 5-years. Nevertheless, 13.1% of individuals with low viraemia at presentation develops CHB within 1 year: 1-year HBV-DNA monitoring resulted the most accurate diagnostic approach that can be limited to at least a half of cases by the single point HBV-DNA/HBsAg quantification. The IC-diagnostic-accuracy combining HBV-DNA/total-anti-HBc/HBcrAg needs to be confirmed in further studies.
Keywords: HBeAg negative CHB; HBsAg clearance; inactive infection; quantitative HBsAg.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.J Clin Virol. 2013 Oct;58(2):401-7. doi: 10.1016/j.jcv.2013.08.010. Epub 2013 Aug 16. J Clin Virol. 2013. PMID: 24004660
-
Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers.Liver Int. 2012 May;32(5):796-802. doi: 10.1111/j.1478-3231.2011.02693.x. Epub 2011 Nov 30. Liver Int. 2012. PMID: 22128792
-
Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.Gastroenterology. 2010 Aug;139(2):483-90. doi: 10.1053/j.gastro.2010.04.052. Epub 2010 May 5. Gastroenterology. 2010. PMID: 20451520
-
The prognosis and management of inactive HBV carriers.Liver Int. 2016 Jan;36 Suppl 1:100-4. doi: 10.1111/liv.13006. Liver Int. 2016. PMID: 26725905 Review.
-
Occult hepatitis B virus infection.Transfus Clin Biol. 2004 Feb;11(1):18-25. doi: 10.1016/j.tracli.2003.11.007. Transfus Clin Biol. 2004. PMID: 14980545 Review.
Cited by
-
HBeAg-negative Patients with Chronic Hepatitis B Virus Infection and Normal Alanine Aminotransferase: Wait or Treat?J Clin Transl Hepatol. 2022 Oct 28;10(5):972-978. doi: 10.14218/JCTH.2021.00443. Epub 2022 Mar 17. J Clin Transl Hepatol. 2022. PMID: 36304490 Free PMC article. Review.
-
Viral Biomarkers in Chronic HBeAg Negative HBV Infection.Genes (Basel). 2018 Sep 27;9(10):469. doi: 10.3390/genes9100469. Genes (Basel). 2018. PMID: 30262738 Free PMC article. Review.
-
Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy.J Clin Med. 2022 Mar 4;11(5):1406. doi: 10.3390/jcm11051406. J Clin Med. 2022. PMID: 35268497 Free PMC article.
-
Nucleos(t)ide analogs to treat patients with positive hepatitis B virus deoxyribonucleic acid and normal alanine transaminase: protocol for an open-label single-center randomized parallel controlled trial.Trials. 2024 Oct 3;25(1):652. doi: 10.1186/s13063-024-08433-x. Trials. 2024. PMID: 39363218 Free PMC article.
-
Necessity of antiviral treatment for patients with chronic hepatitis B in the grey zone based on liver pathology analysis.Ann Med. 2024 Dec;56(1):2399757. doi: 10.1080/07853890.2024.2399757. Epub 2024 Sep 16. Ann Med. 2024. PMID: 39283046 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources